long term impact of glp 1 GLP-1 has changed the conversation around weight loss—but it's important to understand what it can and cannot do. It's not the right choice for everyone, and it's not a replacement for healthy glp 1 gip side effects

This review provides a comprehensive summary of recent progress, opportunities, and challenges in targeting oxidative cell death for cancer therapy

Regulatory agencies in sports have banned its use due to performance-enhancing concerns despite lacking therapeutic validation

Key mechanisms: Directly inhibits NF-B the central transcription factor governing the body's inflammatory cascade Suppresses MAP kinase signalling pathways Reduces pro-inflammatory cytokines including TNF-, IL-1, and IL-6 Acts via PepT1 transporters in intestinal epithelial and immune cells, targeting gut-resident inflammation at the tissue level The evidence: A landmark study published in Gastroenterology demonstrated that nanomolar concentrations of KPV inhibit NF-B and MAP kinase inflammatory pathways and reduce pro-inflammatory cytokine secretion and that oral administration of KPV reduces the incidence of chemically induced colitis in mice as measured by both histology and cytokine expression

There are trade-offs

The matter was remanded back to FDA for reconsideration, and FDA issued a decision in December 2024 confirming the drug shortage was resolved

References Breunig, E., Michel, K., Zeller, F., Seidl, S., Weyhern, C.W.H.V